SEC Form 4 · accession 0000950138-18-000018
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank Scholz
Officer — EVP Glob Ops & Pres Spec Gen
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 7:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Jan 2, 2018 | A | 1,394 | $0.00 | A | 43,844 | D | |
| Ordinary Shares | Jan 2, 2018 | F | 754 | $23.52 | D | 43,090 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Vesting of performance share award granted on January 2, 2015.
- F2Includes 499 shares acquired between March 31, 2017 and June 30, 2017 under the Mallinckrodt employee stock purchase plan.